Recently, the FDA had approvedBristol-Myers Squibb (BMY) immuno-oncology drug Opdivo, for use in patients with hepatocellular carcinoma (liver cancer) who failed prior therapy. These were patients that had already gone through treatment with current first-line therapy of sorafenib (marketed as Nexavar), which is produced by Bayer (OTCPK:BAYZF). In my opinion, this was a good win for the company. That is because it won approval for Opdivo in this patient population. The accelerated approval was based on excellent tumor response rate, and durability of response.
